Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease

K Dutt, A Vasudevan - Medicina, 2024 - mdpi.com
Background: Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn's
disease, necessitates long-term medical therapy to manage symptoms and prevent …

[HTML][HTML] Approach to loss of response to advanced therapies in inflammatory bowel disease

N Vootukuru, A Vasudevan - World Journal of Gastroenterology, 2024 - wjgnet.com
BACKGROUND Remarkable progress over the last decade has equipped clinicians with
many options in the treatment of inflammatory bowel disease. Clinicians now have the …

Risankizumab Concentration but not IL-22 Levels are Associated With Clinical and Biochemical Remission in Patients With Crohn's Disease

X Roblin, E Moschetti, M Barrau, AS Cheifetz… - Clinical …, 2024 - Elsevier
Discussion Our study, using data from real-life clinical practice, is the first to show a positive
association between serum trough RZB concentrations and clinical and biochemical …

[HTML][HTML] Relationship between Ustekinumab trough concentrations and clinical, biochemical and endoscopic outcomes in Crohn's disease: A multi-center nationwide …

M Shehab, I Abdullah, A Alfadhli, F Alrashed - Medicine, 2024 - journals.lww.com
Ustekinumab has been shown to be effective in inducing and maintain clinical and
endoscopic remission in Crohn disease (CD). We aim to assess whether ustekinumab …

Postoperative Ustekinumab Drug Levels and Disease Activity in Patients with Crohn's Disease

J Moskow, T Thurston, A Saleh, A Shah… - Digestive Diseases and …, 2024 - Springer
Aims This study investigated how post-operative ustekinumab levels relate to surgery type,
endoscopic, biochemical, and clinical outcomes in patients with Crohn's Disease. Methods A …